HRD detection predicts sensitivity to platinum-based chemotherapy for ovarian cancer patients in China

Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a biomarker in ovarian cancer patients, especially in the Chinese population.